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Abstract
Background: PDSAFE is an individually-tailored, physiotherapist-delivered, balance, strength and strategy training
programme aimed at preventing falls among people with Parkinson’s. We evaluated the cost-effectiveness of
PDSAFE compared with usual care for people with Parkinson’s at higher risk of falling, from a UK National Health
Service and Personal Social Service perspective.
Methods: Resource use and quality of life data (EQ-5D-3L) were collected from 238 participants randomised to the
PDSAFE intervention and 236 participants randomised to control, at baseline, 3 months, 6 months (primary
outcome), and 12 months. Adjusted cost and quality-adjusted life-years (QALYs) were estimated using generalised
linear models and uncertainty estimated using a non-parametric bootstrap.
Results: Over 6 months, the PDSAFE intervention was associated with an incremental cost of £925 (95% CI £428 to
£1422) and a very small and statistically insignificant QALY gain of 0.008 (95% CI − 0.006 to 0.021). The resulting
incremental cost-effectiveness ratio (ICER) was £120,659 per QALY and the probability of the intervention being
cost-effective at a UK threshold of £30,000/QALY was less than 1%. The ICER varied substantially across subgroups
although no subgroup had an ICER lower than the £30,000 threshold. The result was sensitive to the time horizon
with the ICER reducing to £55,176 per QALY when adopting a 12-month time horizon and assuming a sustained
treatment effect on QoL, nevertheless, the intervention was still not cost-effective according to the current UK
threshold.
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Conclusions: Evidence from this trial suggests that the PDSAFE intervention is unlikely to be cost-effective at 6 months.
The 12-month analysis suggested that the intervention became closer to being cost-effective if quality of life effects
were sustained beyond the intervention period, however this would require confirmation. Further research, including
qualitative studies, should be conducted to better understand the treatment effect of physiotherapy and its impact on
quality of life in people with Parkinson’s given existing mixed evidence on this topic.
Trial registration: ISRCTN48152791. Registered 17 April 2014. http://www.isrctn.com/ISRCTN48152791
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Background
Improving balance and reducing falls are identified as
the leading priority of the James Lind Alliance [1] top 10
priorities for people with Parkinson’s [2]. People with
Parkinson’s are twice as likely to fall as healthy older
people; a recent US study revealed that the overall falls
incidence rate ratio comparing people with Parkinson’s
versus non-Parkinson’s subjects was 2.05 (95% confi-
dence interval (CI) 1.88–2.24), adjusting for comorbidity
and medications [3]. Falling can have serious health and
quality of life consequences such as fractures, [4, 5] im-
mobility and fear of falling [6] leading to dependency
and social isolation [7]. Falling also increases the psycho-
logical burden on informal caregivers, increases personal
costs (e.g. home alteration), [8] as well as costs to the
health care system. A recently published (2018) 10-year
UK cohort study analysed linked health care data from
7060 people with Parkinson’s, and the cost of inpatient
care was found to be £900 per year greater compared to
age and sex matched controls [9]. Among the reasons
for admission to inpatient care (e.g. infection, dementia
etc.), falls and related fractures were most frequently
cited, accounting for 13% of the total cases [10]. In
Germany, direct costs among the people with Parkin-
son’s who experienced falls was considerably higher than
among people with Parkinson’s who did not fall (€3180
and €1300 respectively) due to the longer duration of
hospitalisation [11].
Frequent and repeated falls are not prevented with
medication, [12] however, several studies have shown
that physiotherapy can be beneficial through exercise,
strength and balance training, [13–15] yet it is unclear
whether physiotherapy reduces the rate of falling [16,
17]. A UK multi-centre, single blind, randomised con-
trolled trial, was conducted to evaluate the effectiveness
and cost-effectiveness of a novel, home-based physio-
therapy programme, PDSAFE, compared to usual care
for falls management in people with Parkinson’s [18].
Economic evaluation alongside clinical trials compares
the cost and outcomes of health care interventions im-
plemented in the randomised arm of the trial and makes
recommendations to decision makers regarding inter-
vention cost-effectiveness. The objective of this study
was to estimate the cost-effectiveness of the PDSAFE
intervention compared to usual care in people with Par-
kinson’s who had a history of falling.
Methods
Trial eligibility criteria, baseline characteristics,
intervention, and outcome measures
Between 2014 and 2016, 474 participants were rando-
mised to receive the PDSAFE intervention (n = 238) or
usual care (n = 236) for a six-month period. Patients
were eligible if they: had a confirmed consultant’s diag-
nosis of Parkinson’s; were independently mobile; experi-
enced ≥1 fall in the previous 12months; scored ≥24 on
Mini-Mental State Examination [19]; and were able to
give informed consent, understand and follow com-
mands, and complete a guided personalised exercise and
strategy programme. These participants were on average
aged 71 (SD 7.7) and 73 (SD 7.7) in the intervention and
control group, with a mean of 8 (SD 6.6) and 8 (SD 5.8)
years of diagnosis of Parkinson’s respectively, a median
Hoehn & Yahr scale stage of 3 in both groups, and a
mean Movement Disorder Unified Parkinson’s Disease
Rating Scale (UPDRS) score of 32 (SD 15.2) and 33 (SD
17.3) respectively [18]. The proportion of participants
that had freezing of gait in the past month prior to ran-
domisation was 64% in the intervention group and 59% in
the control group. Both of the groups had a median of 3
falls in the 12months prior to screening, and 78% in the
intervention group and 80% in the control group had re-
peat falling during the same period [18]. In the 3months
prior to randomisation, the intervention and control par-
ticipants had a median of 2 and 1 fall respectively [18].
The trial protocol, including a summary of economic
evaluation methods, and the detailed trial primary out-
come results are published elsewhere [14, 18, 20].
The PDSAFE programme was personalised to each
participant by a physiotherapist through a clinical assess-
ment and targeted specific problems in their home en-
vironment. Exercises and strategies were selected from a
menu of activities and provided to participants in a
booklet accompanied by video vignettes on a DVD. Each
participant was provided up to 12 one-hour sessions.
Participants in the control group received usual care
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plus a DVD on Parkinson’s and one advice session after
trial completion. All participants were assumed on ap-
propriate doses of medications during the trial following
specialist Parkinson’s services. The primary outcome was
the risk of repeat falling during the 6 months post
randomisation.
Overview of economic evaluation methods
A ‘within-trial’ 6-month cost-utility analysis was con-
ducted from the perspective of UK National Health Ser-
vice (NHS) and Personal Social Service (PSS) under the
principle of intention-to-treat, following recommenda-
tions for good practice [21, 22]. Costs included interven-
tion costs and NHS and social care cost. Resource use,
and QoL measured using the EQ-5D-3L instrument [23]
were collected at baseline, 3 and 6 months. Missing data
were imputed using multiple imputation methods [24].
The incremental cost-effectiveness ratio (ICER) was
compared with a £20,000–£30,000 per QALY threshold
currently applied by UK's NICE [21]. Subgroup and sen-
sitivity analyses in relation to cost reduction strategies
and longer follow-up period up to 12 months were con-
ducted. A non-parametric bootstrap with 1000 iterations
was conducted to explore the uncertainty around the
ICER estimate. All analyses were undertaken in STATA/
SE 12.0 [24]. Details of methods were previously pub-
lished elsewhere [25].
Routine resource use
Questionnaires were posted to participants to collect NHS
and social care resource use data. These included: i) pri-
mary care services (GP visits, routine physiotherapy, etc.),
ii) secondary care services (ambulance, hospitalisation,
etc.), iii) social care services (home care visits, meals on
wheels, etc.), and iv) medication use. Medication was not
included in the total costs given the low possibility that
the intervention would impact on the consumption of
medication, as well as the large number of low-cost medi-
cations reported. Unit costs were sourced from the Per-
sonal Social Service Research Unit (PSSRU) [26] and the
NHS National Schedule of Reference Costs [27] for a base
financial year 2016 (Supplementary material 1).
Cost of personalised home-based physiotherapy
The cost of therapy sessions included physiotherapists’
salaries, training, travel, equipment and consumables.
Physiotherapists’ salaries were estimated based on the
UK NHS band six full-time equivalent. Physiotherapists
received 2 days of training, costed as the time spent by
the trainer (lead physiotherapist), room hire and training
materials. Equipment included printed materials and
DVDs of the intervention demonstration provided to
each participant in the intervention group, and a variety
of assisted equipment provided to a proportion of
participants as needed, including weighted vests, balance
pads, and steps. All equipment was retained by the phys-
iotherapists and used across participants. Costs associ-
ated with the equipment were annualised with
a discount rate of 3.5% [21] over the anticipated life span
where appropriate.
Quality of Life (QOL) and Quality Adjusted Life Years
(QALYs)
QoL was measured using the EQ-5D-3L [28] instrument
and utility scores were generated using tariff values pre-
viously elicited from a UK general population sample
[29]. The area-under-the-curve approach was used to es-
timate QALYs where the change between the two as-
sessment points was assumed to be linear [30].
Participants who died had their utility score and re-
source use set to zero from the next assessment point
after death.
Missing data and multiple imputation
Missing cost or EQ-5D-3L utility values were imputed
using multiple imputation with chained equations and
the predictive mean matching method was used [24].
The imputation was conducted separately within the
PDSAFE and control groups. 50 imputed datasets were
created. EQ-5D-3L was imputed at the utility value level
(rather than at the dimension level), and cost items were
imputed as categories (NHS cost excluding hospitalisa-
tion, hospitalisation cost, and social care cost) following
recommended practice [24]. Missingness at item level
was imputed with zero assuming no resource was used if
any other item within the same cost categories was com-
pleted in the questionnaire. Given the relatively high
cost of hospitalisation, any missing data in hospitalisa-
tion were cross checked with falls diaries before imput-
ation for accuracy purposes.
Statistical analysis
Adjusted differences in costs and QALYs between the
randomised groups were estimated using generalised lin-
ear models. Cost and QALYs were estimated using a
Gamma distribution and a normal distribution respect-
ively. Baseline utility scores and costs were adjusted.
Other covariates adjusted were selected based on statis-
tical significance in a regression predicting the likelihood
of missingness from the full list of demographics, med-
ical history, and screening measures. The resulted list of
covariates included: age, gender, Hoehn & Yahr scale,
[31] Montreal Cognitive assessment score, [32] Mini-
Mental State Examination score, [19] presence of dia-
betes, history of myocardial infarction, history of ische-
mic heart disease, history of deep brain stimulation and
presence of an informal carer.
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The method of recycled predictions was used to esti-
mate mean costs and QALYs of each trial arm. The
ICER was estimated by dividing the adjusted cost differ-
ence between the randomised groups by the adjusted
QALY difference. Uncertainty in the ICER estimate was
evaluated using a 1000-iteration bootstrap and the prob-
abilities that the intervention was cost-effective under a
wide range of hypothetical thresholds (£0 - £200,000)
were presented in the cost- effectiveness acceptability
curve.
Sensitivity analysis
A variety of sensitivity analyses were conducted to assess
the impact on the cost-effectiveness results. First, an al-
ternative 12-month time horizon analysis was under-
taken. In part due to funding cessation, 12-month
follow-up data were only available for approximately half
of the participants, and cost, outcome and covariate data
were imputed for the participants who were not followed
up to 12 months. Second, the number of therapy ses-
sions was reduced from the 12 sessions in the base case
as implemented in the trial to alternatives of 10 sessions
and 8 sessions over a six-month period assuming main-
tained QoL, to explore the impact of lowering the inter-
vention costs on the cost-effectiveness result. Next,
complete case analysis was implemented assuming data
were missing completely at random to assess the impact
of missing data on the cost-effectiveness results. Lastly,
the number of routine NHS physiotherapist visits was
excluded from the total cost addressing the possibility that
participants could not differentiate between an NHS or
trial physiotherapist when answering the questionnaire.
Subgroup analysis
Effectiveness of the intervention was differential in four
subgroups [18] and therefore cost-effectiveness analyses
were conducted in subgroups defined by these four cri-
teria. They are: UPDRS scores, Montreal Cognitive as-
sessment cognitive function scores, presence of freezing
symptoms measured by a standardised Freezing of gait
questionnaire [33], and number of retrospective falls.
The incremental effects across the groups were gener-
ated using recycled prediction methods to balance the
covariates.
Results
Intervention cost
The total cost of the PDSAFE intervention was £650 per
participant in the intervention arm (Table 1). The cost
of physiotherapists’ time and travel expenses accounted
for over 95% of the total intervention cost.
Resource use and costs
Over the 6-month period, participants in the interven-
tion group had fewer GP, practice nurse or home care
help visits, though none of the differences was statisti-
cally significant (Supplementary material 2). The most
frequently used social service was home care: on average
Table 1 PDSAFE intervention costs
Item Unit cost (£) Quantity Sum (£)
Therapists training
Trainer (lead therapist) 165 per day 1.75 days 288.75
Room hire 150 per day 2 days 300
Training materials 3.50 per therapist 14 therapists 49
Therapy sessions
Therapist time 43.62 per visit 238 participants * 12 124,578.72
Consumables (clinical notes) 1.20 per visit 238 participants * 12 3427.20
Travel expenses 8 per visit 238 participants * 12 22,848
Patient equipment during the sessions
Printed materials 2 per participant 238 participants 476
CDs 0.08 per participant 238 participants 19.04
Weighted vests 54.16 each 23.8a 1289.01
Balance pads 19.41 each 59.5b 1154.90
Step counts 11.99 each
(6.31c)
15.87d 100.14
Total cost (per patient n = 238) 649.60
Note: a. Approximately 1 in 5 participants used a weighted vest. Each weighted vest was used for two participants for all visits. (238/5)/2 = 23.8
b. Approximately 1 in 2 participants used a balance pad. Each pad was used for two participants for all visits. (238/2)/2 = 59.5
c. Annualised cost over 2 years: K/[(1-(1 + r)-n)/r]. K = 11.99, r = 3.5%, n = 2
d. Approximately 1 in 15 participants used a step count: 238/15 = 15.87
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each participant in the intervention group had 13 visits
compared to 30 visits in the control group. Overall,
there was no statistically significant difference in the cost
of resource use between the groups. The total 6-month
cost of service use per patient was £3137 (95%CI £2602,
£3673) in the intervention group and £3069 (95% £2621,
£3518) in the control group, with a non-statistically sig-
nificant difference of £68 (95%CI -£634, £770).
QoL and QALYs
The completeness of EQ-5D-3L questionnaire at the
month 6 follow-up was 79% (188/238) and 90% (213/
236) for the intervention and control groups respect-
ively. The utility values of the intervention group de-
clined slightly less than the control group in the 6-
month and 12-month periods (Fig. 1). The differences in
utility values between the groups were small (0.031 at
6 months, and 0.017 at 12 months), and not statistically
significant.
Cost-effectiveness base-case analysis
The adjusted costs of the intervention and control group
were £4020 (95%CI £3531, £4510) and £3095 (95%CI
£2694, £3496) respectively, leading to an incremental
cost of £925 (95%CI £428, £1422). The adjusted QALYs
of the intervention and control group were 0.336 (95%CI
0.326, 0.345) and 0.328 (95%CI 0.319, 0.337) respectively,
which resulted an incremental QALY of 0.008 (95%CI
-0.006, 0.021). The resulting ICER was £120,659 per
QALY gained. All the bootstrapped cost-utility pairs
(Fig. 2a) were in the northern quadrants, indicating that
the cost consumed in the intervention group was always
greater than in the control group. Similarly, the majority
of the simulated cost-utility dyads were in the north-east
quadrant, indicating that the intervention was more
likely to improve mean health outcomes than the control
group. The cost-effectiveness plane crossing the y axis in-
dicates that there was a higher degree of uncertainty sur-
rounding the estimate of the incremental QALY than
the estimate of incremental cost, leading to a wide 95%
confidence interval for the estimate of ICER. The cost-
effectiveness acceptability curve (Fig. 2b) shows that the
probability that the intervention was cost-effective at the
£30,000 threshold was 0.5%.
Subgroup and sensitivity analysis
The ICER was above £30,000 for all subgroups indicat-
ing the intervention was not cost-effective in any
Fig. 1 EQ-5D-3L utility values at baseline, 3, 6, and 12 months
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subgroup (Supplementary material Table 3a). The in-
cremental QALYs in the intervention arm for those
who had not experienced freezing episodes was statis-
tically significantly greater (0.021, 95% CI 0.0007,
0.041), although the ICER remained high (=£61,687
per QALY). In the sensitivity analyses, while the
PDSAFE intervention was still not cost-effective com-
pared to the control arm in all scenarios, the ICER
decreased by more than half when estimated over a
12-month time horizon (Supplementary material Table 3b).
Discussion
The results showed that the PDSAFE intervention was
unlikely to be cost-effective from an NHS and PSS’s per-
spective over the trial horizon. There was minimal dif-
ference between arms in the total cost of NHS and
Fig. 2 Cost-effectiveness plane (a) and cost-effectiveness acceptability curve (b) of the PDSAFE intervention vs. usual care
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social service use. The utility values in the intervention
group declined slightly less than the control group over
the trial period, but the difference was minimal and not
statistically significant.
A high degree of uncertainty over the QALYs gained
led to a wide confidence interval in the ICER, which
may be due to the small mean QALY gained and large
variation among the participants. This may also be re-
lated to the limitation of the EQ-5D-3L instrument [34]
in capturing the impact of the PDSAFE intervention
on QoL aspects such as improved falls efficacy and
less fear of falling as identified in the effectiveness
results and a qualitative investigation as part of the
PDSAFE trial [25].
Sensitivity analyses indicated that the intervention was
more likely to be cost-effective if a 12-month time horizon
was adopted. If the difference lasts beyond the 12-month
follow-up point, the probability of the intervention being
cost-effective would be expected to increase because the
cost of intervention would be recouped over a longer time
horizon and incremental QALY gain would be larger, how-
ever further research would be needed to fully examine this.
Exploratory analysis of the observed 6 month data found
the treatment effect to be greater among the participants
who did not provide 12-month data compared to those
who did. This suggests that if those participants were
followed up to 12months, a potentially greater treatment
effect at 12months might have emerged. This may also
suggest that the participants who received the intervention
later may gain more benefit than the participants who re-
ceived the intervention early, possibly due to the learning
curve of the trial physiotherapists, however these could all
be due to chance.
Several studies have evaluated the cost-effectiveness of
exercise programmes or physiotherapy programmes previ-
ously and the results were mixed. Clarke et al. (2016) eval-
uated effectiveness and cost-effectiveness of physiotherapy
and occupational therapy versus no therapy in the PD
REHAB randomised controlled trial among 762 patients
with mild to moderate Parkinson’s disease [35]. They
found that individualised physiotherapy and occupational
therapy did not have immediate (3 months) or long-term
(15months) clinically meaningful improvements in activ-
ities of daily living or QoL measured by PDQ-39. Al-
though no difference in primary outcome was found, the
ICER was only £3493/QALY (−£169,371 to £176,358) with
50.5% probability to be under the £20,000 threshold. The
authors, noting the wide confidence interval surrounding
the ICER as well as the insignificant QALY gain, con-
cluded that the cost-effectiveness result was contingent on
a clinically meaningful primary outcome which had not
been found. An earlier trial (2012) by Fletcher et al. re-
ported a more positive result in favour of a 10-week exer-
cise programme with 0.03 (− 0.02 to 0.08) incremental
QALY gained and £35 less health and social care costs,
which suggested the intervention was dominant with ap-
proximately 80% probability that the intervention was
cost-effective [36]. The intervention cost £76 per partici-
pant for the complete 10-week group sessions in commu-
nity settings in this trial. Notably, the cost-effectiveness
analysis alongside this trial incorporated only 93 of the
130 participants who were randomised, and there was no
imputation strategy for missing data hence these results
could be subject to selection bias. An Australian study
evaluated the cost-effectiveness of a similar exercise inter-
vention led by a physical therapist (a mixture of group and
individual sessions) among Parkinson’s population and es-
timated the cost to be $A574 per fall averted and a ICER
of $A338,800/QALY with a 0.005 QALY gain over a 6-
month period [37]. The intervention cost was estimated to
be $A1,010 (in 2012 Australian dollars, equivalent to
£559) per participant which incorporated monthly group
exercise classes, and 2 to 4 home visits from the therapist
over 6 months. They concluded that the intervention was
cost-effective when using a threshold of $A2,000 per fall
prevented however the ICER estimate was far over the UK
equivalent threshold £20,000 to £30,000 per QALY gained.
Compared to the current study, both Clarke et al. and
Fletcher et al. [35, 36] reported much more positive cost-
effectiveness estimates favouring the intervention, due to
the lower intervention costs and higher QALYs gained.
The result from the Australian study is consistent with the
current study, reporting similar intervention cost (£559,
vs. £649 for PDSAFE) and similar QALY (0.005 vs. 0.008
for PDSAFE) gained. Overall the QALY gained in the
three earlier studies and the PDSAFE trial were small and
measured with substantial uncertainty. Further studies
should be conducted to better understand the treatment
effect of physiotherapy and its impact on QALY.
Conclusions
Over the 6-month period, the PDSAFE intervention was
associated with a small, statistically insignificant mean
QALY gain with large uncertainty, leading to a large ICER
with a wide confidence interval. The uncertainty analysis
revealed that the probability of the intervention being
cost-effective was 0.5% suggesting that the PDSAFE inter-
vention is unlikely to be cost-effective from the NHS and
PSS perspective. Sensitivity analysis showed that even if
the number of PDSAFE physiotherapy sessions were re-
duced from 12 to 8, the ICER would still be three times
higher than the current NICE threshold due to the un-
changed incremental QALY gain. Therefore, cost reduc-
tion strategies only, such as changing home-based to
group sessions, are unlikely to result in the intervention
becoming cost-effective unless effectiveness also improves.
The 12-month analysis, however, suggested that the inter-
vention may become cost-effective were the effect to be
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sustained beyond the intervention period however this
would require a study with longer follow-up beyond 12
months.
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